



SUVEN Life Sciences

Communication to investors
March 2011



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

FINANCIAL QUICK VIEW

Quarter 4 – Mar 2011



• Growth in revenue	27.66%
• Growth in PAT	121.54%
• Growth in EBIDTA	110.73%
• Growth in Pre-R&D EBIDTA	1.52%
• R&D cost on revenue	16.50%

FINANCIAL QUICK VIEW

Year ended Mar 2011



• Growth in revenue	16.86%
• Growth in PAT	48.55%
• Growth in EBIDTA	7.44%
• Growth in Pre-R&D EBIDTA	-4.31%
• R&D cost on revenue	20.53%


MAJOR PROFITABILITY RATIOS



	Q4 Mar 11	Q4 Mar 10	YE Mar 11	YE Mar 10
PAT to Income	7.53%	4.34%	6.86%	5.39%
EBIDTA to Income	11.62%	7.04%	9.24%	10.05%
Cash Flow to Income	10.46%	7.96%	10.45%	9.47%
Pre-R&D EBITDA to Income	28.12%	35.37%	29.77%	36.36%




INCOME COMPARISON






PROFIT COMPARISON






PRE-R&D EBIDTA






PRE-R&D CASHFLOW






R & D – EXPENDITURE





EBIDTA COMPARISON





Updates for the Year


During the quarter there were major qualitative achievements in **granting of 21 product patents from all over the world** for Suven's drug discovery pipeline which consists of 12 molecules on 6 targets in CNS arena which are at various stages of preclinical and clinical development and these Patents are valid until 2025 in addition to the clinical candidate SUVN-502 for Alzheimer's and Schizophrenia.

Suven Life Sciences bags Pharmexcil's Gold "Patent Award"

SUVEN'S UNIT-III RECEIVES US FDA ACCEPTANCE



SUVEN an end to end bio-pharmaceutical solutions company



Collaborative Research Partner (CRP) ...
Seamless transition